# TOFO Insulin Combination Trial

Study · id `cardio:ct-nct02201004` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02201004](<https://clinicaltrials.gov/study/NCT02201004>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02201004

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 211 participants.

## Technical summary

Registry record NCT02201004. Randomized; double masking; primary purpose treatment. Start 2014-06 (registry gives no type); primary completion 2016-01 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 211 participants (enrolled count; ClinicalTrials.gov record NCT02201004, source copy `cardio:ctgov-nct02201004-2017-10-11`, retrieved 2026-10-26)
- Start date: 2014-06 (registry gives no type) (ClinicalTrials.gov record NCT02201004, source copy `cardio:ctgov-nct02201004-2017-10-11`, retrieved 2026-10-26)
- Primary completion: 2016-01 (actual) (ClinicalTrials.gov record NCT02201004, source copy `cardio:ctgov-nct02201004-2017-10-11`, retrieved 2026-10-26)
- Completion: 2016-10 (actual) (ClinicalTrials.gov record NCT02201004, source copy `cardio:ctgov-nct02201004-2017-10-11`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT02201004, source copy `cardio:ctgov-nct02201004-2017-10-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02201004-2017-10-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: TOFO Insulin Combination Trial
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): TOFOGLIFLOZIN CSG452
- Intervention (Drug): insulin
- Intervention (Drug): placebo
- Lead sponsor: Sanofi
- Lead sponsor class: INDUSTRY
- Collaborator: Kowa Company, Ltd.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Sanofi (`cardio:org-sanofi`)
- Registry lists this organization as a collaborator: Kowa Company, Ltd. (`cardio:org-kowa-company-ltd`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): Results of a 16-week randomized, double-blind, placebo-controlled multicentre trial (`cardio:pubmed-28371205`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: be6d37bb8ec116ae2d7fbb07a93c2a466123031a60c5fe73a13323d5cc3d63e3
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
